Blueprint Medicines
A global precision therapy company that develops therapies for people with cancer and blood disorders.
The US biotech company's assets include avapritinib, BLU-554 and BLU-667, selective investigational kinase medicines developed that have demonstrated clinical proof-of-concept in genomically defined subsets of patients with cancer.
Latest Blueprint Medicines News & Features
22 February 2024
9 January 2024
20 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze